In Diagnosis Of Juvenile Inflammatory Arthritis In Children, Sonography Complements Physical Exam

Juvenile Inflammatory Arthritis (JIA) is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability. Research has shown that sonography with power Doppler can facilitate making assessments in joint activity and sub-clinical disease, according to research being presented at the 2011 American Roentgen Ray Society's annual meeting.

Rheumatoid Arthritis Campaign Surpasses $30 Million Goal

The American College of Rheumatology Research and Education Foundation announced its Within Our Reach: Finding a Cure for Rheumatoid Arthritis campaign has surpassed its initial $30 million fundraising goal and has already funded $24.4 million in RA research grants.

The campaign raised a total of $30,719,054 from 245 donors (making an average campaign gift of $125,384) with patients accounting for over $3 million.

Rheumatoid Arthritis Drug Simponi (golimumab) Gets Provisional Approval By NICE, UK

Rheumatoid arthritis patients who have not responded well to previous treatment will be eligible for National Health Service (NHS) funded treatment with Simponi combined with methotrexate, NICE (National Institute for Clinical Excellence) announced. NICE decides which drugs and therapies can be included in the NHS.

Simponi, to be administered alongside methotrexate is now provisionally recommended for adult patients whose rheumatoid arthritis symptoms did not respond well to conventional DMARDS (disease-modifying antirheumatic drugs), including methotrexate.

Immune System Proteins Might Protect Children From Rare, Deadly Inflammation

By analyzing complex interactions of the immune system in an animal study, pediatric researchers have found potential tools for controlling a life-threatening condition called a cytokine storm that may strike children who have juvenile arthritis and other autoimmune diseases.

Osteoarthritis -- More Common As Obesity Rises

Osteoarthritis is a degenerative joint disease and the most common cause of disability today. It was once considered a problem of the old but it is now commonly diagnosed in those as young as the mid-twenties and early thirties. According to the Arthritis Foundation, about four million, quality-adjusted life years are lost due to knee osteoarthritis alone. They further conclude that those who are obese are also more likely to develop advanced, end-stage disease than those who maintain a healthy weight.

Novel Role Identified For A Protein That Could Lead To New Treatments For Rheumatoid Arthritis

A new study by rheumatologists at Hospital for Special Surgery in New York has shown that a powerful pro-inflammatory protein, tumor necrosis factor (TNF), can also suppress aspects of inflammation. The researchers say the identification of the mechanism of how this occurs could potentially lead to new treatments for diseases such as rheumatoid arthritis. The study was published May 22 online in advance of publication in the journal Nature Immunology.

NRAS Launches Care Plan To Help Enhance Patient Self-Management Of Rheumatoid Arthritis, UK

Today the National Rheumatoid Arthritis Society (NRAS) has launched the NRAS Care Plan, a patient-held record designed to improve a patient's ability to self-manage their Rheumatoid Arthritis.

Waking Up To The Morning Symptoms Of Rheumatoid Arthritis (RA)

European-wide research published today in the Annals of the Rheumatic Diseases1,2,3 reveals the real impact of the morning symptoms of rheumatoid arthritis (RA) on a patient's working ability and quality of life, with 83% of those with severe morning stiffness (n=170), agreeing that the difficulties caused by morning stiffness and pain control their lives.1

Rheumatoid Arthritis: Studies Show Vectra(TM) DA Can Track Early Response To Therapy

Crescendo Bioscience™ has announced data indicating that Vectra™ DA, a first-in-class multi-biomarker blood test used to assess rheumatoid arthritis (RA) disease activity, provides physicians with an objective measure which may help determine whether patients are responding to therapy. Additional studies show that the score from the Vectra DA algorithm has the potential to predict progressive joint damage and is robust in RA patients who have common comorbid conditions.

Tofacitinib Shown To Be An Efficacious Treatment For Active RA

Results of a Phase III study presented at the EULAR 2011 Annual Congress show that at 6 months, 58.3 percent of patients who had previously not responded to treatment with DMARDs, achieved ACR20 response (a 20 percent improvement in symptoms) when treated with the novel oral Janus kinase inhibitor tofacitinib at 10mg BID compared to 31.2 percent in the placebo group. Significant improvements were also observed in the 5 mg BID dose.